The tiny wire-mesh tubes called stents that prop open arteries cleared during an angioplasty have undergone a series of improvements since they were first developed 30 years ago. Early bare-metal stents were prone to clogging up, a problem known as restenosis. Drug-eluting stents prevented that problem but led to another: blood clot formation. Today’s third-generation stents address that issue but still require the use of blood-thinning drugs after a stent placement. Researchers are working on bioabsorbable stents that would gradually disappear and not require as much use of blood thinners.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.